Prosecution Insights
Last updated: August 16, 2026
Application No. 18/977,587

SILICA POWDER FOR COSMETIC PREPARATIONS, AND COSMETIC PREPARATION

Non-Final OA §102§103
Filed
Dec 11, 2024
Priority
Jun 13, 2022 — JP 2022-095198 +2 more
Examiner
WEBB, WALTER E
Art Unit
Tech Center
Assignee
Agc Si-Tech Co. Ltd.
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 7m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
464 granted / 1000 resolved
-13.6% vs TC avg
Strong +19% interview lift
Without
With
+18.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
48 currently pending
Career history
1049
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
52.1%
+12.1% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
16.2%
-23.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1000 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-7 is/are rejected under 35 U.S.C. 102(a)(1)) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Horie et al., (CN115304068). Horie et al. teaches “a method for producing silicon dioxide particles and use thereof in cosmetic compositions. The present disclosure also relates to a spherical shape of silicon dioxide particles comprising (SiO4/2) repeating units” (Abstract). Concerning claim 5, the silicon particles are also taught to have “a D90/D10 particles size distribution of about 1.3 or less as measured by laser diffraction and is spherical and has a sphericity of 0.9 or more as defined by a minor axis/major axis” (p. 2, 2nd paragraph of translation). “[T]he silica particles have a median particle size (D50) of about 0.5µm-50µm” and “a BET surface area of about 0.1m2/g to about 100m2/g” (p. 3, 4th and 5th paragraphs) The cosmetic products comprising the silicon dioxide particles have “excellent spreadability, feeling and good adhesion to the skin, less cosmetic collapse . . . “ (p. 3, 2nd paragraph), which speaks to a degree of aggregation of 60% or more insofar as it is a condition where “an interaction between the silica particles is large and adhesion between the particles is improved, resulting in a soft and moist feel when spread on skin” (Specification p. 5, para. [0016]). Concerning claim 6, the prior art teaches several cosmetic formulations comprising the spherical silica particles, e.g. “Powdery eye shadow” (see p. 11 of translation). Concerning claim 7, the cosmetic formulations “further comprises one or more personal care ingredients”, such as, “fumed silica or hydrated silicon dioxide” (silica powders other than the silica powder for a cosmetic material) (p. 8 last paragraph through p. 9). The prior art teaches a specific embodiment of spherical particles having a D50 of “3.8 µm, the particle since distribution D90/D10 is 1.11 and the BET specific surface area is 1.32m2/g” (p. 9 Example 1), as per claims 4-5. Since the prior art contains substantially the same components in the same relative proportions as instantly claimed, i.e. silica particles having a sphericity of 0.9 or more, it would be expected to inherently possess the same chemical and physical properties, such as a degree of aggregation of 60% or more, a stress relaxation rate of 18% or less, a shearing cohesion of 2.0 kPa or more. The prior art is anticipatory insofar as it teaches silica particles having an average circularity of 0.75 or more. Assuming for the sake of argument that the prior art teaches is not specific enough to give rise to anticipation it would have been obvious to provide silica particles having an average circularity of 0.75 or more of cosmetic material, since the prior art teaches silicon particles for cosmetic formulations having a sphericity of 0.9 or more. Conclusion Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 11, 2024
Application Filed
Jul 24, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702644
PHARMACEUTICAL COMPOSITION COMPRISING IBUPROFEN AND ARGININE
2y 2m to grant Granted Aug 11, 2026
Patent 12678406
PROCESS OF PREPARING ICE-BASED LIPID NANOPARTICLES
4y 9m to grant Granted Jul 14, 2026
Patent 12677850
STEVIA BLENDS CONTAINING REBAUDIOSIDE B
2y 9m to grant Granted Jul 14, 2026
Patent 12654163
VIRAL INFECTIONS - TREATMENT WITH CONVALESCENT PLASMA/SERUM
3y 8m to grant Granted Jun 16, 2026
Patent 12653773
Oral Care Compositions Comprising Hops Beta Acid And Amino Acid
2y 4m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
65%
With Interview (+18.7%)
3y 3m (~1y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1000 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month